FGFR2b required higher rH C /A concentrations (≥100 nM and 68 nM, respectively). Furthermore, 3 43 addition of the GT1b ganglioside to the culture media resulted in increased dimerization, whereas 44 a ganglioside mutant variant of H C /A (rH C /A W1266L;Y1267S) showed decreased dimerization. 45 Interestingly, reduced dimerization was also observed with an SV2 mutant variant of H C/ A (rH C /A 46 T1145A;T1146A). These results support a model wherein BoNT/A interacts with FGFRs, 47 48 49 Current word count: 299 words 50 PLOS one Abstract length: 300 words 51 52 53 54 55 56 57 58 59 60 4 61 65 specificity and high potency of BoNT/A has allowed its use in the treatment of a large number of 66 medical and aesthetic conditions [3, 5-7], relying on injection of picomolar (pM) concentrations 67 of the toxin. Though BoNT/A has been the subject of extensive study, greater understanding of 68 the complex mechanism associated with BoNT/A's neuronal specificity and cellular entry could 69 lead to further therapeutic applications. 70 BoNT/A is a single-chain protein activated by proteolytic cleavage to form a 150 kDa di-71 chain molecule. The di-chain is comprised of a light chain (L C /A) which encodes a Zn 2+ dependent 72 endopeptidase (~50 kDa), linked by a single disulfide bond and non-covalent interactions to a 73~100 kDa heavy chain (HC) containing the receptor binding and translocation domains [8]. The 74 50 kDa receptor binding domain, H C /A, is located at the C-terminal half of the HC and mediates 75 specific binding and internalization of the toxin into neurons. Following internalization, the 76 translocation domain (H N ) of BoNT/A residing at the N-terminal half of the HC facilitates the 77 translocation of L C /A from the endocytic vesicle into the cytosol. Once in the cytosol, L C /A 78 enzymatically cleaves the soluble N-ethylmaleimide-sensitive factor attachment protein receptor 79 (SNARE), synaptosomal-associated protein 25 (SNAP-25) [9, 10], which is essential for mediating 80 vesicular fusion and exocytosis. Cleavage of SNAP-25 leads to inhibition of 81 neurotransmitter/neuropeptide release, including acetylcholine, from neuronal cells and is
ABSTRACT 26 Clostridium botulinum neurotoxin serotype A (BoNT/A) is a potent neurotoxin that also serves as 27 an effective therapeutic for a variety of neuromuscular and glandular diseases and disorders. The 28 observed pharmacological effect of BoNT/A is due to specific targeting and entry into motor 29 nerve terminals within muscles followed by cleavage of the SNARE protein, SNAP-25, inducing a 30 block in neurotransmission and temporary muscular paralysis. Specific binding and 31 internalization of BoNT/A into neuronal cells are mediated by its binding domain (H C /A), which 32 binds to GT1b ganglioside and protein cell surface receptors. Previously, fibroblast growth factor 33 receptor 3 (FGFR3) was identified as a BoNT/A receptor, in addition to synaptic vesicle protein 34 (SV2). To further study BoNT/A interactions with FGFRs, an FCS & TIRF receptor dimerization 35 assay was developed to measure dimerization of FGFRs in live cells, as FGFR dimerization can be 36 considered an indirect measure for receptor-ligand binding interaction and downstream 37 signaling. The ability of H C /A to facilitate dimerization of three FGFR subtypes (FGFR1-3) was 38 assessed. Recombinant H C /A (rH C /A) was shown to dimerize FGFR subtypes in the rank order 39 FGFR3c > FGFR2b > FGFR1c. With potencies (EC 50 values) defined as the concentration of ligand 40 required to dimerize 50% of the receptors, wild type rH C /A dimerized FGFR3c with an EC 50 of 24 41 nM, similar to FGF9, a native FGFR3c ligand, which had an EC 50 of 15 nM, while FGFR1c and gangliosides, and SV2 on the cell surface to facilitate cell uptake. 62 Botulinum Neurotoxin Type A (BoNT/A) is a 150 kDa metalloenzyme belonging to the 63 family of neurotoxins produced by Clostridium botulinum which causes temporary muscle 64 paralysis by inhibiting acetylcholine release at the neuromuscular junction [1] [2] [3] [4] . The neuronal 5 82 responsible for BoNT/A's observed pharmacological effects on smooth and skeletal muscles and 83 glands [1, 11, 12] . 84 Initially, BoNT/A binds with relatively low affinity (K D ~200 nM) to gangliosides, including 85 GT1b, which are abundant at the presynaptic membrane and serve to trap and concentrate 86 BoNT/A within the extracellular matrix [13] [14] [15] [16] . H C /A mutations (W1266L;Y1267S) [16] have been 87 identified which disrupt binding to GT1b and likely additional gangliosides (e.g., GD1a, GD1b, 88 GQ1b, and GM1), which bind to BoNT/A with lower affinity compared to GT1b [14] [15] [16] [17] . Once 89 anchored close to the membrane, BoNT/A interacts with one or more relative high affinity 90 protein receptors, including the synaptic vesicle protein, SV2 (K D ~100 nM) [18] [19] [20] [21] [22] [23] , and FGFR3 91 (K D ~15 nM) [24, 25] . Mutations within H C /A that disrupt binding to SV2 have been identified, 92 including T1145A;T1146A [20] , and G1292R [19] . The observed in vivo selectivity of BoNT/A for 93 specific classes of neuronal cells is likely due to avidity upon binding to multiple receptors, which 94 may also serve as a requirement to trigger internalization into the neuronal cell via endocytosis 95 [13] [14] [15] [16] . Interaction of BoNT/A with multiple receptors could provide an evolutionary advantage 96 for the toxin, since it decreases the likelihood of host specific mutations resulting in toxin 97 resistance. A similar strategy is known from other pathogens, including Herpes simplex virus 98 (HSV) [26] , Trypanosoma cruzi (Chaga's disease) [27, 28] , and human immunodeficiency virus 99 (HIV) [29, 30] . Influenza A virus infection has also been suggested to involve FGFRs [31] . Previous 100 protein complex immunoprecipitation results demonstrated an interaction between FGFRs and 101 SV2 in neuronal cells [24] , further suggesting the possibility of a multi-receptor BoNT/A complex.
INTRODUCTION

102
FGFR3 is one of four receptor-tyrosine kinases (FGFR1-4) that act as receptors for FGFs. 103 FGFR1-3, but not FGFR4, exist in three different splice variants, a-c, which differ in their 6 104 extracellular ligand binding domains, each with differing ligand binding affinities and specificities 105 [32, 33] . The a isoform variants terminate early, resulting in a secreted extracellular FGF-binding 106 protein [34] [35] [36] [37] . The b isoform variants, including FGFR2b, are primarily expressed in tissues of 107 epithelial (surface tissue) origin, while the c isoform variants, including FGFR1c and FGFR3c, are 108 primarily expressed in tissues of mesenchymal (connective tissue) origin. Native ligands for FGFRs 109 are generally produced by either epithelial or mesenchymal cells and act on opposite tissue type 110 FGFRs. An exception is FGF1, which binds to both b and c FGFR isoforms [38, 39] . There are 22 111 known FGF ligands that bind with different affinity and selectivity to the different FGFR splice 112 variants. For example, FGF4 binds to FGFR1c > 2c > 3c, while FGF9 binds to FGFR3c > 2c > 1c and 113 3b, and FGF10 binds to FGFR2b > 1b [35, 37, 39, 40] . Most FGFs interact locally with FGFRs in a 114 paracrine or autocrine manner, although a number of FGFs, including FGF19, FGF21, and FGF23, 115 act like hormones in an endocrine manner [36, 41] . Selectivity and affinity in vivo is achieved via 116 interactions with co-receptors, including: heparin, heparan sulfate (HS), neural cell adhesion 117 molecule (NCAM), cadherin, integrin, Klotho, anosmin, neuropilin, and fibronectin, which 118 interact with both FGFs and FGFRs [42, 43] . Gangliosides have also been reported to be co-119 receptors for FGFRs, affecting ligand binding, receptor dimerization, receptor activity, and 120 subcellular localization [44, 45] . 121 This tissue specific expression of the ligands, receptors, and co-receptors, guides tissue 122 and organ growth and development. FGFR signaling upon ligand binding and receptor activation 123 is associated with numerous cellular functions, including development, homeostasis, and 124 metabolism. FGFRs are activated by dimerization induced by co-receptor and ligand binding, 7 125 which enables the cytoplasmic kinase domains to transphosphorylate one another at specific 126 tyrosine residues [34] [35] [36] [37] 46] . 127 As noted above, the binding domain of botulinum neurotoxin, rH C /A, has been shown to 128 bind FGFR in vitro and in cells [47, 48] . To further study wild-type (wt) and mutant variants of FCS & TIRF receptor dimerization assay for studying receptor dimerization in live cells. 234 235 In the TIRF (Total Internal Reflection Fluorescence) method, the optics of the instrument 236 are adjusted such that the exciting light will be reflected from the interface, i.e., the glass surface 237 supporting the cell. However, some of the energy of the incident beam will penetrate through 238 the interface, creating what is termed an evanescent field which extends a very short distance 239 on the order of 100 nm into the cell. Hence, this evanescent beam will only be able to excite to homodimerize under addition of a ligand, a 2x increase in the average molecular brightness 256 would be observed compared to the monomeric brightness standard, and the number of pixels 257 with 2x normalized average molecular brightness would increase (Figure 2B; S2 Figure) . (Figure 2A) , perhaps indicative of aggregated receptor proteins. Immobile fluorophores do 281 not fluctuate, so any potentially aggregated protein will not be analyzed. Calculation of the 282 average molecular brightness, in the absence of ligand, showed that the values for FGFR3c-AF488 283 were higher (1.1-1.2-fold) than the Alexa488 fluorophore molecular brightness monomer 284 standard, suggesting that 10-20%of the receptors are in preformed dimers. Dimerization in the 285 absence of ligand has previously been reported for EGFR under overexpression conditions that AF488 were treated with rH C /A. In parallel, two native FGFR ligands were analyzed; FGF9, a 302 known agonist ligand for FGFR3c and FGF10, a known agonist ligand for FGFR2b but not FGFR3c. 303 As expected, addition of FGF9 resulted in a dose-dependent increase in average normalized 304 molecular brightness, whereas treatment with FGF10 did not (Figure 3) . EC 50 values for FGFR3c 305 dimerization, defined as concentration of ligand resulting in 50% receptor dimerization, were 18 306 nM (95% CI [12, 24] ) for FGF9 and >200 nM for FGF10 (Table 1) . Notably, the ability of rH C /A to 307 dimerize FGFR3c was similar to FGF9 with an EC 50 of 27 nM (95% CI; 18, 41), suggesting that rH C /A 308 has FGFR3c agonist-like properties (Figure 3; Table 1 ). As the FGFR subtypes (FGFR1-4) share a high degree of structural and functional 354 homology, it was of interest to assess the affinity of rH C /A to other FGFRs, including FGFR1c and 355 FGFR2b (Figure 5; Table 1 ). As expected, ligands known to bind specifically to these receptors while no increase in molecular brightness was observed in the presence of rHc/A, even with 408 upwards of 150 nM (EC 50 >150 nM) ( Figure S2; Table 1 ), suggesting that rH C /A has a high degree 409 of specificity for FGFRs. (Figure 2) . The fact that a plateau of normalized brightness at ~2 (or dimer species) was observed 437 for the non-clustering molecular brightness may indicate that these cells have been saturated The specific binding site on H C /A for SV2 has been identified as an exposed beta-strand 471 loop in the center of the binding domain [19, 20, 22, 79] . The observation that a variant of H C /A 472 (T1145A;T1146A [20]) with mutations in residues important for SV2 binding shows reduced 473 ability to dimerize FGFR3c suggests that these residues, directly or indirectly, affect binding to 474 FGFRs. Perhaps the binding site for FGFR and SV2 overlap and binding of BoNT/A and SV2 is 475 sequential. However, it is also possible that the reduced binding affinity observed by the H 
